tv3
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM T-3
FOR APPLICATIONS FOR QUALIFICATION OF INDENTURES
UNDER THE TRUST INDENTURE ACT OF 1939
SAFEGUARD SCIENTIFICS, INC.
(Name of Applicant)
435 Devon Park Drive, Building 800, Wayne, PA 19087-1945
(Address of principal executive offices)
SECURITIES TO BE ISSUED UNDER THE INDENTURE TO BE QUALIFIED
|
|
|
TITLE OF CLASS |
|
AMOUNT |
10.125% Convertible Senior
Debentures due 2014
|
|
Up to aggregate principal
amount of $46,936,000* |
Approximate date of proposed Exchange:
As soon as practicable after the date of this Application for Qualification
Name and address of agent for service:
Brian J. Sisko
Senior Vice President and General Counsel
Safeguard Scientifics, Inc.
435 Devon Park Drive, Building 800
Wayne, Pennsylvania 19087-1945
With a copy to:
Justin W. Chairman
Morgan, Lewis & Bockius LLP
1701 Market Street
Philadelphia, Pennsylvania 19103
|
|
|
* |
|
The actual aggregate principal amount of 10.125% Convertible Senior Debentures due 2014 to be
issued under the Indenture, which is defined below, may be less and depends upon the aggregate
amount of 2.625% Convertible Senior Debentures due 2024 that are exchanged as described in Item 2. |
The Applicant hereby amends this application for qualification on such date or dates as may be
necessary to delay its effectiveness until: (1) the 20th day after the filing of a further
amendment which specifically states that it shall supersede this application for qualification or
(2) such date as the Securities and Exchange Commission, acting pursuant to Section 307(c) of the
Trust Indenture Act of 1939, as amended, may determine upon the written request of the Applicant.
GENERAL
ITEM 1. GENERAL INFORMATION.
(a) Safeguard Scientifics, Inc. (the Company or Applicant) is a corporation.
(b) The Company is organized under the laws of the Commonwealth of Pennsylvania.
ITEM 2. SECURITIES ACT EXEMPTION APPLICABLE.
The
Company may issue up to $46,936,000 aggregate principal amount of its new 10.125% Convertible
Senior Debentures due 2014 (the New Notes). The Company may issue the New Notes in one or more
exchange transactions with certain holders (the Holders) of the Companys existing 2.625%
Convertible Senior Debentures due 2024 (the Old Notes) pursuant to one or more exchange
agreements, the form of which is filed as Exhibit T3E hereto and which is incorporated herein by
reference. The New Notes will be issued under the indenture (the Indenture) to be qualified by
this Application for Qualification on Form T-3 (the Application). No exchanges of Old Notes will
be accepted, and no New Notes will be issued, before the effectiveness of this Application.
The New Notes will be issued by the Company to the Holders in reliance on the exemption provided in
Section 3(a)(9) of the Securities Act of 1933, as amended. No sales of securities of the same class
as the New Notes have been or are to be made by the Company by or through an underwriter at or
about the same time as the exchange for which the exemption is claimed. No consideration has been,
or is to be, given, directly or indirectly, to any person in connection with such exchange, except
for payment by the Company of (i) a flat advisory fee for a financial advisor which advised the
Company with respect to the terms and mechanics of the exchange offer and performed services that
were administrative, ministerial or mechanical in nature, (ii) the fees and expenses of its legal
advisors for their legal services, and (iii) fees charged by U.S. Bank National Association, for
its services as trustee under the Indenture. None of the Holders has made or will be requested to
make any cash payment to the Company in connection with such exchange, other than payment of any
applicable taxes.
AFFILIATIONS
ITEM 3. AFFILIATES.
For purposes of this Application only, the Companys directors and executive officers may be deemed
to be affiliates of the Company. See Item 4 Directors and Executive Officers for a list of the
Companys directors and executive officers, which list is incorporated herein by reference.
The following is a list of subsidiaries of the Company that may be deemed to be affiliates of the
Company as of the date of this Application. The Company owns, directly or indirectly, 100% of the
outstanding capital stock or other equity interests of each of its subsidiaries, except where
otherwise indicated.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage Owned by |
|
Name of Affiliate |
|
Jurisdiction of Incorporation |
|
|
Applicant |
|
Bonfield Fund Management, L.P. |
|
Delaware |
|
|
93.5 |
% |
Bonfield VII, Ltd. |
|
British Virgin Islands |
|
|
100 |
% |
Bonfield Partners Capital, L.P. |
|
Delaware |
|
|
91.3 |
% |
Novitas Capital Management, L.P. |
|
Delaware |
|
|
100 |
% |
Novitas Capital II Management, L.P. |
|
Pennsylvania |
|
|
100 |
% |
Safeguard Capital Management, Inc. |
|
Delaware |
|
|
100 |
% |
Safeguard Delaware, Inc. |
|
Delaware |
|
|
100 |
% |
Safeguard Fund Management, Inc. |
|
Delaware |
|
|
100 |
% |
Safeguard Fund Management, L.P. |
|
Delaware |
|
|
93.1 |
% |
Safeguard Partners Capital, L.P. |
|
Delaware |
|
|
91.1 |
% |
Safeguard Scientifics (Delaware), Inc. |
|
Delaware |
|
|
100 |
% |
Safeguard Technologies, Inc. |
|
Delaware |
|
|
100 |
% |
SSI Management Company, Inc. |
|
Delaware |
|
|
100 |
% |
SSI Partnership Holdings (Pennsylvania), Inc. |
|
Pennsylvania |
|
|
100 |
% |
MANAGEMENT AND CONTROL
ITEM 4. DIRECTORS AND EXECUTIVE OFFICERS.
The following table sets forth the names of, and all offices held by, all directors and executive
officers (as defined in Sections 303(5) and 303(6) of the Trust Indenture Act of 1939, as amended),
respectively, of the Company. The mailing address for each executive officer and director listed
below is c/o Safeguard Scientifics, Inc., Attention: General Counsel, 435 Devon Park Drive,
Building 800, Wayne, PA 19087-1945.
|
|
|
Name |
|
Position |
Peter J. Boni
|
|
President and Chief Executive Officer, Director |
Michael J. Cody
|
|
Director |
Julie A. Dobson
|
|
Director |
Andrew E. Lietz
|
|
Director |
George MacKenzie
|
|
Director |
George D. McClelland
|
|
Director |
Jack L. Messman
|
|
Director |
John J. Roberts
|
|
Director |
Dr. Robert J. Rosenthal
|
|
Director |
James A. Datin
|
|
Executive Vice President and Managing Director, Life Sciences |
Kevin L. Kemmerer
|
|
Executive Vice President and Managing Director, Technology |
Brian J. Sisko
|
|
Senior Vice President and General Counsel |
Stephen T. Zarrilli
|
|
Senior Vice President and Chief Financial Officer |
Steven J. Grenfell
|
|
Vice President, Operations |
Gary J. Kurtzman, M.D.
|
|
Vice President and Managing Director, Life Sciences |
Jeffrey B. McGroarty
|
|
Vice President and Corporate Controller |
Robert L. R. Munden
|
|
Vice President, Corporate Counsel and Assistant Secretary |
Erik B. Rasmussen
|
|
Vice President and Managing Director, Technology |
John E. Shave
|
|
Vice President, Business Development and Corporate Communications |
Deirdre Blackburn
|
|
Secretary |
ITEM 5. PRINCIPAL OWNERS OF VOTING SECURITIES.
The following sets forth information as to each person owning 10% or more of the voting securities
of the Company as of the date of this Application.
None.
ITEM 6. UNDERWRITERS.
(a) No person acted as an underwriter for the Companys securities within the past three
years.
(b) No person is acting as an underwriter for the issuance of the New Notes proposed to be
offered pursuant to the Indenture.
ITEM 7. CAPITALIZATION.
(a) Set forth below is certain information as to each authorized class of securities of the Company
as of March 3, 2010.
|
|
|
|
|
|
|
|
|
Title of Class |
|
Amount Authorized |
|
|
Amount Outstanding |
|
Preferred Stock, $0.10 par value |
|
1,000,000 shares |
|
None |
Common Stock, $0.10 par value |
|
83,333,333 shares |
|
20,444,180 shares |
2.625% Convertible Senior
Debentures due 2024 |
|
$150,000,000 |
|
$78,225,000 |
b) Holders of shares of the Companys Common Stock are entitled to one vote per share of Common
Stock on all matters on which holders of shares of the Common Stock are entitled to vote. Holders
of the Companys Common Stock are entitled to receive notice of and attend all meetings of the
shareholders of the Company.
3
INDENTURE SECURITIES
ITEM 8. ANALYSIS OF INDENTURE PROVISIONS.
The New Notes will be issued under the Indenture to be entered into between the Company and U.S.
Bank National Association, as trustee (the Trustee). The following is a general description of
certain provisions of the Indenture. This description is qualified in its entirety by reference to
the form of Indenture filed as Exhibit T3C hereto and incorporated herein by reference. Capitalized
terms used in this Item 8 and not defined herein have the meanings assigned to them in the
Indenture.
(A) Events of Defaults; Withholding of Notice.
The following are Events of Default under the terms of the Indenture:
|
|
|
the Companys failure to pay the principal of any of the New Notes when due and payable; |
|
|
|
|
the Companys failure to pay any Interest upon any of the New Notes when due and payable
where such failure to pay continues for 30 days; |
|
|
|
|
the Companys failure to deliver Common Stock, cash or both following conversion of the
New Notes by a Debentureholder or the Company, as the case may be, where such failure to
pay continues for 10 Business Days; |
|
|
|
|
the Companys failure to provide a Designated Event Notice; |
|
|
|
|
the Companys failure to pay Indebtedness when due and payable, or upon acceleration by
the Company or a subsidiary of the Company, where the aggregate principal amount with
respect to such failure to pay exceeds $25 million and such Indebtedness has not been
discharged or such acceleration has not been rescinded or annulled within a period of 30
days after written notice of such failure to pay is given to the Trustee and to holders of
at least 25% in aggregate principal amount of the New Notes then Outstanding; |
|
|
|
|
the Companys failure to pay any final judgments aggregating more than $25 million; |
|
|
|
|
the Companys failure to perform its obligations under the New Notes or the Indenture
where such failure to perform continues for 60 days after written notice of such failure to
perform has been given to the Company; |
|
|
|
|
the Escrow Agreement ceases to be in full force and effect or enforceable prior to its
expiration in accordance with its terms; |
|
|
|
|
the Company issues securities in exchange for any of the Companys 2.625% Convertible
Senior Debentures due 2024 and fails to comply with Section 4.09 of the Indenture in
connection with such issuance of convertible debentures; and |
|
|
|
|
certain events in bankruptcy, insolvency or reorganization occur with respect to the
Company or its properties (Bankruptcy). |
If an Event of Default occurs, other than an Event of Default relating to Bankruptcy, unless the
aggregate principal amount of all New Notes is already due and payable, then either the Trustee or
holders of not less than 25% in aggregate principal amount of the New Notes then Outstanding may
declare the principal of all of the New Notes and the Interest accrued and unpaid thereon to be due
and payable immediately. If an Event of Default relating to Bankruptcy occurs, the principal of
all the New Notes and the Interest accrued and unpaid thereon shall immediately and automatically
become due and payable.
After any such acceleration, but before a judgment or decree for the payment of such acceleration,
the holders of a majority in aggregate principal amount of the New Notes then Outstanding may waive
and rescind all Events of Default if the Company pays a sum sufficient to pay all matured
installments of Interest upon all of the New Notes and the principal of all New Notes that is due
otherwise than by such acceleration, plus interest on overdue installments of Interest and on the
principal.
4
In case the Company fails to pay (a) any installment of Interest due upon any of the New Notes and
such default continues for a period of 30 days, or (b) any payment of the principal of any of the
New Notes when due and payable, then, upon demand of the Trustee, the Company will pay to the
Trustee, for the benefit of all of the Debentureholders, the entire amount that is due and payable
on such New Notes for Interest or principal, as the case may be, plus interest upon the overdue
principal and upon the overdue installments of Interest at the rate borne by the New Notes plus 1%
and a sum sufficient to cover the costs and expenses of collection.
No Debentureholder will have any right to institute any proceeding under the Indenture or for the
appointment of a receiver or a trustee, or for any other remedy under the Indenture, unless:
|
|
|
the Debentureholder has previously given the Trustee written notice of a continuing
Event of Default; |
|
|
|
|
the holders of at least 25% in aggregate principal amount of the New Notes then
Outstanding have made a written request and have offered reasonable security and indemnity
to the Trustee to institute such proceeding under its own name as Trustee; and |
|
|
|
|
the Trustee has failed to institute such proceeding within 60 days after such notice,
request and offer. |
The above limitations, however, do not apply to a suit instituted by a Debentureholder for the
right to convert any New Note in accordance with the terms of the Indenture.
The holders of a majority in aggregate principal amount of the New Notes then Outstanding may
generally waive any default or Event of Default under the New Notes and the Indenture except:
|
|
|
a default in the payment of Interest on, or the principal of, the New Notes; |
|
|
|
|
a failure by the Company to convert any New Notes in accordance with the terms of the
Indenture; or |
|
|
|
|
a default in respect of a covenant that cannot be modified or amended without the
consent of the holders of all of the outstanding New Notes then Outstanding. |
(B) Authentication and Delivery of Securities under the Indenture and Application of Proceeds
Thereof.
The New Notes to be issued under the Indenture may be executed by manual or facsimile signature on
behalf of the Company by the Chief Executive Officer, the President, or any Vice President of the
Company and delivered to the Trustee. The Trustee shall authenticate and deliver such New Notes
along with a certificate of authentication. The Trustee is authorized to appoint an authenticating
agent to act on the Trustees behalf in connection with the authorization and delivery of the New
Notes.
There will be no proceeds from the issuance of the New Notes because the New Notes are being issued
in exchange for the Old Notes.
(C) Release of any Note Collateral Subject to the Lien of the Indenture.
None. The New Notes are unsecured.
(D) Satisfaction and Discharge of the Indenture.
The Company may discharge its obligations under the Indenture while the New Notes remain
outstanding if (a) the Company delivers to the Trustee for cancellation all authenticated and
non-canceled New Notes, or (b) all of the New Notes not canceled or delivered to the Trustee for
cancellation are due and payable within one year, and, in either case, the Company has (x)
deposited with the Trustee an amount sufficient to pay and discharge all of the outstanding New
Notes on their scheduled maturity, including Interest and any other sums payable under the
Indenture, and (y) delivered to the Trustee a verification report as to such amount from an
independent certified accountant or other financial professional.
5
(E) Repurchase of Debentures by the Company upon a Designated Event.
If a Designated Event occurs at any time prior to the maturity of the New Notes, then each
Debentureholder will have the right to require the Company to repurchase all of the
Debentureholders New Notes, or any part that is a multiple of $1,000 principal amount, on a date
that is between 20 and 35 Business Days after the date of notice from the Company of the Designated
Event. The Company will repurchase the New Notes at a repurchase price equal to 100% of the
principal amount of the New Notes, together with any unpaid Interest on the New Notes.
(F) Conversion of Debentures.
Subject to and in compliance with the provisions of the Indenture, the New Notes are convertible at
the option of a Debentureholder or the Company, or as a result of certain reclassifications,
consolidations, mergers or sale transactions of the Company, as the case may be, at the Conversion
Rate in effect at the time of conversion. The initial Conversion Rate is equal to 60.6061 shares of
Common Stock per $1,000 principal amount of New Notes, which is equivalent to a conversion price of
approximately $16.50 per share of Common Stock. Unless the Company has made an Irrevocable Net
Share Settlement Election, the Company may satisfy its conversion obligations by delivering, at the
Companys election, shares of Common Stock, cash or a combination of cash and shares of Common
Stock.
The Company will not issue fractional shares of Common Stock upon conversion of New Notes but will
instead pay cash for the fractional amount based upon the Closing Sale Price of the Common Stock on
the last Trading Day prior to the date of conversion.
i. Conversion by Debentureholders.
A Debentureholder is entitled, at such Debentureholders option, to convert the principal amount of
a New Note at any time prior to the close of business on the Business Day immediately preceding
March 15, 2013, upon the satisfaction of one of the following conditions:
|
|
|
during any fiscal quarter commencing after June 30, 2010 if the Closing Sales Price per
share of the Common Stock for at least 20 Trading Days (whether or not consecutive) during
the period of the 30 consecutive Trading Days ending on the last Trading Day of the
preceding fiscal quarter is greater than or equal to 120% of the Conversion Price on each
such Trading Day; |
|
|
|
|
during the five Business Day period commencing on the Business Day immediately following
any 10 consecutive Trading Day period in which the Trading Price per $1,000 principal
amount of New Notes was less than 100% of the product of the Closing Sale Price per share
of the Common Stock multiplied by the Conversion Rate on each such Trading Day; |
|
|
|
|
a Fundamental Change occurs; or |
|
|
|
|
the Company exercises its option to manditorily convert the New Notes. |
ii. Mandatory Conversion by the Company.
At any time on or after March 16, 2012 through the maturity date of the New Notes, the Company may
cause any of the New Notes to be mandatorily converted at the Conversion Rate then in effect if the
Closing Sale Price per share of the Common Stock for at least 20 Trading Days (whether or not
consecutive) in a period of 30 consecutive Trading Days exceeds 130% of the Conversion Price on the
date of conversion.
iii. Conversion upon Reclassification, Consolidation, Merger or Sale.
In the event of any reclassification, consolidation or merger of the Company, or in the event of
certain sales or conveyances of the Companys securities or assets (each, a Transaction), then
the Company and the Trustee shall execute a supplemental indenture providing that each New Note
shall be changed into a right to convert into the Reference Property of such Transaction that a
holder of a number of shares of Common Stock equal to the Conversion Rate immediately prior to such
Transaction would have received on account of such Transaction.
6
(G) Evidence of Compliance with Conditions and Covenants.
The Company is required to furnish to the Trustee, on an annual basis, a statement by one of its
principal officers as to whether or not the Company, to such officers knowledge, is in default in
the performance or observance of any of the terms, provisions and conditions of the Indenture,
specifying any known defaults and the nature and status of such defaults.
ITEM 9. OTHER OBLIGORS.
None.
CONTENTS OF APPLICATION FOR QUALIFICATION
This application for qualification comprises:
(a) Pages numbered 1 to 7, consecutively.
(b) The statement of eligibility and qualification on Form T-1 of the Trustee under the
Indenture to be qualified (included as Exhibit T3G hereto).
(c) The following exhibits in addition to those filed as part of the Form T-1 statement of
eligibility and qualification of the Trustee:
|
|
|
Exhibit T3A.1
|
|
Second Amended and Restated Articles of Incorporation of the Company. Incorporated by reference to the Companys
Current Report on Form 8-K filed with the Securities and Exchange Commission on October 25, 2007. |
|
|
|
Exhibit T3A.2
|
|
Amendment to Second Amended and Restated Articles of Incorporation of the Company. Incorporated by reference to
the Companys Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2009. |
|
|
|
Exhibit T3B
|
|
Amended and Restated By-laws of the Company. Incorporated by reference to the Companys Current Report on Form
8-K filed with the Securities and Exchange Commission on October 25, 2007. |
|
|
|
Exhibit T3C*
|
|
Form of Indenture between the Company and U.S. Bank National Association, as trustee. |
|
|
|
Exhibit T3D
|
|
Not applicable. |
|
|
|
Exhibit T3E.1*
|
|
Form of Exchange Agreement between the Company and certain holders of the Old Notes. |
|
|
|
Exhibit T3E.2*
|
|
Form of Escrow Agreement between the Company and U.S. Bank National Association, as trustee, and U.S. Bank
National Association, as escrow agent. |
|
|
|
Exhibit T3F
|
|
Cross-Reference Sheet showing the location in the Indenture of the provisions inserted therein pursuant to
Sections 310 through 318(a), inclusive, of the Trust Indenture Act of 1939, as amended. Included as part of
Exhibit T3C herewith. |
|
|
|
Exhibit T3G*
|
|
Statement of eligibility and qualification of U.S. Bank National Association, as trustee, on Form T-1. |
7
SIGNATURE
Pursuant to the requirements of the Trust Indenture Act of 1939, the applicant, Safeguard
Scientifics, Inc., a corporation organized and existing under the laws of the Commonwealth of
Pennsylvania, has duly caused this application to be signed on its behalf by the undersigned,
thereunto duly authorized, and its seal to be hereunto affixed and attested, all in the City of
Wayne, and Commonwealth of Pennsylvania, on the 11th day of March, 2010.
|
|
|
|
|
|
|
|
|
|
|
(SEAL) |
|
|
|
SAFEGUARD SCIENTIFICS, INC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attest:
|
|
/s/ Jessica L. Jensen
|
|
|
|
By:
|
|
/s/ Brian J. Sisko
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jessica L. Jensen |
|
|
|
|
|
Name: Brian J. Sisko |
|
|
|
|
|
|
|
|
|
|
Title: Senior Vice President and General Counsel |
|
|
8
EXHIBIT INDEX
|
|
|
EXHIBIT |
|
DESCRIPTION |
|
|
|
Exhibit T3A.1
|
|
Second Amended and Restated Articles of Incorporation of the Company.
Incorporated by reference to the Companys Current Report on Form 8-K
filed with the Securities and Exchange Commission on October 25,
2007. |
|
|
|
Exhibit T3A.2
|
|
Amendment to Second Amended and Restated Articles of Incorporation of
the Company. Incorporated by reference to the Companys Current
Report on Form 8-K filed with the Securities and Exchange Commission
on August 27, 2009. |
|
|
|
Exhibit T3B
|
|
Amended and Restated By-laws of the Company. Incorporated by
reference to the Companys Current Report on Form 8-K filed with the
Securities and Exchange Commission on October 25, 2007. |
|
|
|
Exhibit T3C*
|
|
Form of Indenture between the Company and U.S. Bank National
Association, as trustee. |
|
|
|
Exhibit T3D
|
|
Not applicable. |
|
|
|
Exhibit T3E.1*
|
|
Form of Exchange Agreement between the Company and certain holders of
the Old Notes. |
|
|
|
Exhibit T3E.2*
|
|
Form of Escrow Agreement between the Company and U.S. Bank National
Association, as trustee, and U.S. Bank National Association, as
escrow agent. |
|
|
|
Exhibit T3F
|
|
Cross-Reference Sheet showing the location in the Indenture of the
provisions inserted therein pursuant to Sections 310 through 318(a),
inclusive, of the Trust Indenture Act of 1939, as amended. Included
as part of Exhibit T3C herewith. |
|
|
|
Exhibit T3G*
|
|
Statement of eligibility and qualification of the Trustee on Form T-1. |
9